1/Treatment of Myeloma:
- Transplant Eligible: (HR/SR)Dara/RVd
- Ineligible SR (DRd preferred)
Ineligible HR (VRd)
- Maintenance SR: lenalidomide
- Maintenance HR: VR (less evidence)
- 1st Relapse (HR/SR)Dara based therapy
- post triple RRMM: CAR-T then BCMA TCE then GPRC5D
#mmsm #myeloma #MedTwitter #MedEd #USMIRC @USMIRCNEWS @OncoAlert
2/Although 1q is considered as a High risk I still treat it as standard risk till I see more studies to show the impact of treatment on the outcomes!
- Regarding EMD (soft tissue) they are considered HR and treated within that group #mmsm #myeloma #MedTwitter #MedEd #USMIRC @USMIRCNEWS @OncoAlert
3/Transplant is still the standard of care for pts who are eligible! Even if they are in sCR after induction therapy
I don’t use consolidation therapy #mmsm #myeloma #MedTwitter #MedEd #USMIRC @USMIRCNEWS @OncoAlert
Hematology and Medical Oncology conference/ Kansas: Updates from ASCO 2023 #mmsm #myeloma #MedTwitter #MedEd #USMIRC Relapse myeloma still a challenge! 3 classes (IMiDs, PI and CD38 MoA) played a role to improve survival & we are looking to see BCMA Directed therapy added
BCMA CAR-T based on 2 RCT showed improved PFS compared to SOC and that is enough for me to change SOC to either Ide-Cel/Cilta-Cel #mmsm #myeloma #MedTwitter #MedEd #USMIRC
TT2 targeting BCMA/GPRC5D might be the next level in triple/Penta RRMM with RR of 87-96%, PFS 21 months! Though we might have issues with AEs #mmsm #myeloma #MedTwitter #MedEd #USMIRC